ADAG vs SMTI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ADAG's Piotroski F-Score of 4/9 indicates weak financial health, with negative profitability and high operating losses, but the company shows strong earnings surprise momentum and improving Q/Q EPS growth. Despite a lack of Altman Z-Score and Graham Number, the stock trades at a premium valuation (Price/Sales: 1886.09) due to high growth expectations in a sector with elevated average revenue growth. Insider sentiment is neutral, and analyst target price suggests significant upside potential. The recent 1-year return of +109.6% and strong quarterly beat rate support a bullish technical and earnings narrative.
SMTI exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 8.13. While the company maintains an impressive gross margin of 92.71%, this is offset by consistent net losses and a track record of massive earnings misses (average surprise of -587.40% over the last 4 quarters). There is a stark disconnect between the 'Strong Buy' analyst consensus and the underlying deterministic health metrics, which suggest high insolvency risk. The stock's long-term price trajectory is sharply negative, despite a recent short-term bounce.
Compare Another Pair
Related Comparisons
ADAG vs SMTI: Head-to-Head Comparison
This page compares Adagene Inc. (ADAG) and Sanara MedTech Inc. (SMTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.